Clinical Ovarian and Other Gynecologic Cancer最新文献

{"title":"Small-Cell Carcinoma in Association With a Mature Cystic Teratoma of the Ovary: A Case Report With Literature Review","authors":"Karina E. Hew , Kimberley Studeman , Panayotis Ledakis , Arvind Bakhru , Neil B. Rosenshein","doi":"10.1016/j.cogc.2013.12.006","DOIUrl":"10.1016/j.cogc.2013.12.006","url":null,"abstract":"","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 53-57"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2013.12.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84122778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Morbidity and Clinical Response After a 2-Week Versus 6-Week Interval From Debulking Surgery to Adjuvant Chemotherapy in Epithelial Ovarian Cancer","authors":"Mohamad Nasir Shafiee ,&nbsp;Azmaniza Baharuddin ,&nbsp;Maiza Tusimin ,&nbsp;Nirmala Kampan ,&nbsp;Arifuddin Djuanna ,&nbsp;Ahmad Zailani Hatta Mohd Dali","doi":"10.1016/j.cogc.2013.12.005","DOIUrl":"10.1016/j.cogc.2013.12.005","url":null,"abstract":"<div><h3>Background</h3><p>The purpose of this study was to determine the effect of time interval between debulking surgery to adjuvant chemotherapy on the short-term morbidity and carcinoma antigen (CA)-125 level.</p></div><div><h3>Patients and Methods</h3><p>A total of 43 patients with primary debulking surgery for operable stage epithelial ovarian cancer (stage IB to IIIC) from January 2008 to January 2010 were analyzed prospectively. The participants were randomized into 2 groups. The surgical–chemotherapy interval group 2 (SCI2) (n = 22) received adjuvant chemotherapy (carboplatin and paclitaxel) within 2 weeks after primary debulking surgery and the SCI6 (n = 21) group received the same chemotherapy agents 6 weeks after the primary surgery. A computerized randomization technique was used.</p></div><div><h3>Results</h3><p>Participants in the SCI2 group had a better CA-125 reduction after 6 cycles of chemotherapy (<em>P</em> &lt; .005) compared with the SCI6 group. The incidence of anemia was more significant in the SCI2 group (<em>P</em> &lt; .005) than in the other group. However, there were no significant differences in wound breakdown, neutropenia, thrombocytopenia, and clinical response of chemotherapy between the 2 groups.</p></div><div><h3>Conclusion</h3><p>Time interval between primary surgery to the commencement of adjuvant chemotherapy had no significant effect on short-term morbidity, but had an improved effect on biochemical (CA-125) response.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 25-30"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2013.12.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90995897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Is There a Role for Maintenance Therapy?","authors":"Beth Cronin ,&nbsp;Katina Robison ,&nbsp;Christina Raker ,&nbsp;Richard Moore ,&nbsp;Cornelius O. Granai ,&nbsp;Don S. Dizon","doi":"10.1016/j.cogc.2014.06.007","DOIUrl":"10.1016/j.cogc.2014.06.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Ovarian cancer is the fifth leading cause of death in women. PLD has been effective in recurrent ovarian cancer, but the ideal treatment length is unknown. We hypothesized that patients with regression or stabilization of disease while receiving PLD, who continued with prolonged treatment, would have increased PFS.</p></div><div><h3>Patients and Methods</h3><p>A retrospective chart review was performed of women with recurrent ovarian, fallopian tube, primary peritoneal, or uterine papillary serous carcinoma, who received 6 or more cycles of PLD without evidence of progression. Evaluation for progression was based on carcinoma antigen 125, physical examination, and imaging studies.</p></div><div><h3>Results</h3><p>Of the 30 patients meeting criteria for inclusion, 13 patients (43%) stopped treatment at best response (median, 6 cycles) and 17 (57%) continued treatment until disease progression (median, 11 cycles). Patients treated to best response experienced a significantly shorter PFS compared with those who continued treatment until progression, median 10 versus 15 months (<em>P</em> = .009). There was a trend toward improved OS in the prolonged therapy group of 42.5 months (range, 12-84) versus 23 months in the standard therapy group (range, 17-98; <em>P</em> = .56).</p></div><div><h3>Conclusion</h3><p>Our data suggest that prolonged PLD treatment to progression is associated with a PFS advantage compared with treatment to best response. In the absence of toxicity, this treatment paradigm should be considered.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 17-20"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76881804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of a Female Adnexal Tumor of Probable Wolffian Origin Complicated by Intercurrent Disseminated Intravascular Coagulation","authors":"John V. Brown III ,&nbsp;Veronica Rausei-Mills ,&nbsp;Christopher P. Crum ,&nbsp;Bram H. Goldstein","doi":"10.1016/j.cogc.2014.06.005","DOIUrl":"10.1016/j.cogc.2014.06.005","url":null,"abstract":"","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 58-61"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73143107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for Women Receiving Bevacizumab for Treatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center","authors":"Katina Robison ,&nbsp;Courtney Olson ,&nbsp;Bachir J. Sakr ,&nbsp;Tina Rizack ,&nbsp;Robert Legare ,&nbsp;Ashley Stuckey ,&nbsp;C.O. Granai ,&nbsp;Don S. Dizon","doi":"10.1016/j.cogc.2013.12.004","DOIUrl":"10.1016/j.cogc.2013.12.004","url":null,"abstract":"<div><h3>Background</h3><p>The main objective of this study was to determine the incidence of severe toxicity associated with bevacizumab use in women with ovarian cancer compared with that in women with other solid tumors.</p></div><div><h3>Patients and Methods</h3><p>This retrospective cohort study was performed by evaluating women treated with single-agent or combination bevacizumab in the Program in Women's Oncology between January 2004 and May 2009. Data was collected from electronic and office-based medical records. Toxicity was assessed according to the National Cancer Institute's Common Toxicity Criteria version 3.0 guidelines. A total of 103 women were treated with bevacizumab: 41 women (40%) with ovarian cancer and 62 (60%) with other solid tumors.</p></div><div><h3>Results</h3><p>There was no increase in the number of toxic effects seen in patients treated for ovarian cancer versus other tumor types. However, GI perforations were seen in 7.3% of women with ovarian cancer, whereas none were seen in those treated for other cancers (<em>P</em> = .06). More than 1 bevacizumab-related toxic effect (hazard ratio [HR], 2.74; 95% CI, 1.35-5.55) and treatment with bevacizumab after 3 prior lines of chemotherapy (HR, 2.44; 95% CI, 1.159-5.129) were associated with an increase in mortality in women with ovarian cancer. We found no significant difference in the incidence of bevacizumab-related toxicities when comparing ovarian cancer to other cancers. However, ovarian cancer patients did appear to have a statistically nonsignificant higher percentage of GI perforations.</p></div><div><h3>Conclusion</h3><p>Further studies evaluating patient factors associated with increased risk of toxicities may be warranted to assist with appropriate patient selection prior to bevacizumab use.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 21-24"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2013.12.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78449326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Grade Astrocytoma Arising in a Mature Ovarian Teratoma in an Adolescent","authors":"Yousef R. Badran ,&nbsp;Fatima N. Obeidat ,&nbsp;Mazen A. Freij","doi":"10.1016/j.cogc.2014.06.001","DOIUrl":"10.1016/j.cogc.2014.06.001","url":null,"abstract":"","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 62-64"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75495289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization Program of Diagnostic, Therapeutic, and Rehabilitation Measures for the Cervical Background Diseases and Precancer","authors":"Badretdinova F. Flarida,&nbsp;Shamil K. Gantsev,&nbsp;Vladimir B. Trubin","doi":"10.1016/j.cogc.2014.02.001","DOIUrl":"10.1016/j.cogc.2014.02.001","url":null,"abstract":"","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 7-10"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74850992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Late Radiation Proctitis Among Patients Treated for Cervical Cancer: A Comparative Study Between Linear Accelerator and Cobalt Teletherapy","authors":"Kannan Ram Abhinav,&nbsp;M.G. Janaki,&nbsp;T.R. Arul Ponni,&nbsp;A.S. Kirthi Koushik,&nbsp;S. Mohan Kumar,&nbsp;Alva Ram Charith,&nbsp;Harjani Ritika,&nbsp;S. Arvind","doi":"10.1016/j.cogc.2014.03.001","DOIUrl":"10.1016/j.cogc.2014.03.001","url":null,"abstract":"<div><h3>Background</h3><p>Concerns have been raised over adequate target volume coverage with conventional 2-dimensional planning owing to wide variations in pelvic anatomy between individual patients. To improve tumor volume coverage, increasing numbers of patients are being treated with 3-dimensional conformal radiotherapy (3DCRT), resulting in increased treatment volume as opposed to conventional planning. This study compares the occurrence of late radiation proctitis among patients with carcinoma of the cervix treated with 3DCRT using a linear accelerator (LINAC) versus conventional therapy using a telecobalt unit.</p></div><div><h3>Patients and Methods</h3><p>A total of 66 patients with carcinoma of the cervix treated with curative intent between August 2006 and August 2012, having a minimum of 6 months of posttreatment follow-up, were reviewed retrospectively. Whole-pelvis irradiation was administered in cobalt teletherapy using the box-field technique (33 patients) or using 3DCRT on a 6-MV LINAC (33 patients), followed by low-dose-rate intracavitary brachytherapy to a dose of 30 Gy.</p></div><div><h3>Results</h3><p>The median ages of patients treated on cobalt teletherapy and LINAC were 50 and 52 years, respectively, and the median follow-up durations were 24 and 18 months, respectively. Seven patients (21%) developed radiation proctitis in the cobalt teletherapy arm, compared with 12 patients (36%) in the LINAC arm (<em>P</em> = .03; χ² test).</p></div><div><h3>Conclusion</h3><p>There is a significant increase in the incidence of late radiation proctitis in patients treated with the 3DCRT technique compared with the conventional technique. The effect of associated factors such as rectal dose during brachytherapy needs to be studied before a definitive conclusion can be drawn.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 46-49"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88725792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Obesity on the Time to Recurrence in Ovarian Cancer: A Retrospective Study","authors":"Karina E. Hew ,&nbsp;Arvind Bakhru ,&nbsp;Evan Harrison ,&nbsp;Mehmet O. Turan ,&nbsp;Ryan MacDonald ,&nbsp;Dwight D. Im ,&nbsp;Neil B. Rosenshein","doi":"10.1016/j.cogc.2014.02.002","DOIUrl":"10.1016/j.cogc.2014.02.002","url":null,"abstract":"<div><h3>Introduction/Background</h3><p>The objective of this study was to examine whether obesity affects the time to recurrence in primary epithelial ovarian cancer.</p></div><div><h3>Patients and Methods</h3><p>A multicenter retrospective chart review was performed between 2004 and 2009. Three hundred seventy patients were eligible for analysis. Demographic and clinicopathological variables and treatment-related data were collected. Women with a body mass index (BMI) &gt; 30 were categorized as obese. The time to recurrence was quantified in terms of months. Survival analyses were performed using the Kaplan-Meier method and compared using log-rank testing.</p></div><div><h3>Results</h3><p>One hundred thirty (35%) obese patients were compared with 240 (65%) nonobese patients. A recurrence was documented in 125 (47.9%) nonobese patients and 49 (37.7%) obese patients. Time to recurrence between both BMI groups was identical, at 15 months (<em>P</em> = 1.0). The progression-free survival was similar in obese and nonobese subjects (<em>P</em> = .118).</p></div><div><h3>Conclusion</h3><p>Obesity does not affect the recurrence time in patients with primary ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 31-35"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87168873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer","authors":"Christa I. Nagel,&nbsp;William N. Denson,&nbsp;Debra L. Richardson,&nbsp;Siobhan M. Kehoe,&nbsp;David S. Miller,&nbsp;Jayanthi S. Lea","doi":"10.1016/j.cogc.2014.06.004","DOIUrl":"10.1016/j.cogc.2014.06.004","url":null,"abstract":"<div><h3>Introduction</h3><p>A large proportion of patients with cervical cancer have a lower socioeconomic background with inherent barriers to clinical trial participation. The present authors hypothesized that patients participating in a clinical trial would have better outcomes compared with those not enrolled in a trial. The objective was to review the clinical outcomes of women with recurrent cervical cancer treated on a clinical trial versus those treated off trial.</p></div><div><h3>Patients and Methods</h3><p>This was a retrospective cohort study of women treated for recurrent cervical cancer on versus off clinical trial between 1998 and 2010. Women participating in Gynecologic Oncology Group clinical trials for recurrent cervical cancer were identified and matched 1:1 with women treated off trial based on age within 10 years, ethnicity, stage at initial diagnosis, histology, primary treatment, and baseline renal function.</p></div><div><h3>Results</h3><p>A total of 60 women with recurrent cervical cancer were identified; 30 were treated for their recurrence on a clinical trial and were matched to 30 treated off trial. The median number of salvage regimens was 1.0 for the trial group (range, 1-5) and 1.5 for the off-trial group (range, 1-5) (<em>P</em> = .74). There was no significant difference in the number of cycles of chemotherapy completed on versus off trial (7.5 vs. 5.9; <em>P</em> = .44). There was also no significant difference in progression-free and overall survival from time of recurrence on trial and off trial (4.2 vs. 3.1 months [<em>P</em> = .75] and 15.0 vs. 13.8 months [<em>P</em> = .64], respectively).</p></div><div><h3>Conclusion</h3><p>This study found that the progression-free survival and overall survival are similar between women treated with chemotherapy on or off trial for cervical cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 42-45"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88990992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}